<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02292069</url>
  </required_header>
  <id_info>
    <org_study_id>10-VIN-107</org_study_id>
    <nct_id>NCT02292069</nct_id>
  </id_info>
  <brief_title>Bioavailability Study of Amlodipine Besylate/Atorvastatin Calcium Tablets 10/80 mg Under Fed Condition</brief_title>
  <official_title>Open Label, Randomized, Two-treatment, Two-period, Two-sequence, Oral Bioequivalence Study of Amlodipine Besylate/Atorvastatin Calcium Tablets 10mg/80mg Under Fed Condition</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to assess the bioequivalence between Amlodipine besylate/Atorvastatin calcium
      Tablets 10mg/80mg of Dr. Reddy's Laboratories Limited, India and CADUET® (amlodipine besylate
      and atorvastatin calcium) tablets 10mg/80mg of Pfizer Ireland Pharmaceuticals Dublin, Ireland
      in healthy, adult,human subjects under Fed conditions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open label, randomized, two-treatment, two-period, two-sequence, oral bioequivalence study of
      Amlodipine besylate/Atorvastatin calcium Tablets 10mg/80mg under Fed conditions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under curve (AUC)</measure>
    <time_frame>The post dose samples of 4.0 mL were drawn at 0.50, 1.00, 2.00, 3.00, 4.00, 5.00, 6.00, 7.00, 8.00, 10.00, 11.00, 12.00, 16.00, 24.00, 36.00, 48.00 and 72.00 hours for Amlodipine assay</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under curve (AUC)</measure>
    <time_frame>post dose samples of 4.0mL were drawn at 0.25, 0.50, 0.75, 1.00, 1.25, 1.50, 1.75, 2.00, 2.25, 2.50, 2.75, 3.00, 3.33, 3.67, 4.00, 4.50, 5.00, 6.00, 8.00, 10.00, 12.00, 16.00, 24.00, 36.00, 48.00 and 72.00 hours for Atorvastatin assay</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Amlodipine besylate/Atorvastatin calcium tablets 10/80 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Amlodipine besylate/Atorvastatin calcium tablets 10/80 mg of Dr. Reddys Laboratories Limited</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Caduet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Caduet® 10/80 mg tablets of Pfizer, Ireland</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine besylate/Atorvastatin calcium</intervention_name>
    <description>Amlodipine besylate/Atorvastatin calcium 10/80 mg</description>
    <arm_group_label>Amlodipine besylate/Atorvastatin calcium tablets 10/80 mg</arm_group_label>
    <arm_group_label>Caduet</arm_group_label>
    <other_name>Caduet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects aged between 18 and 45 years (both inclusive).

          2. Subjects' weight within normal range according to normal values for Body Mass Index
             (18.5 to 24.9 kg/m2) with minimum of 50 kg weight.

          3. Subjects with normal health as determined by personal medical history, clinical
             examination and laboratory examinations within the clinically acceptable reference
             range.

          4. Subjects having normal 12-lead electrocardiogram (ECG).

          5. Subjects having normal chest X-Ray (P/A view) whose X-Ray was taken not more than 6
             months prior to the dosing of Period 01.

          6. Subjects having negative urine screen for drugs of abuse (including amphetamines,
             barbiturates, benzodiazepines, marijuana, cocaine, and morphine).

          7. Subjects having negative alcohol breath test.

          8. Subjects willing to adhere to the protocol requirements and to provide written
             informed consent.

        Exclusion Criteria:

          1. Hypersensitivity to Amlodipine and Atorvastatin or related class of drugs.

          2. History or presence of significant cardiovascular, pulmonary, hepatic, renal,
             gastrointestinal, endocrine, immunological, dermatological, neurological or
             psychiatric disease or disorder.

          3. Any treatment which could bring about induction or inhibition of hepatic microsomal
             enzyme system within 1 month of the study starting.

          4. History or presence of significant alcoholism or drug abuse.

          5. History or presence of significant smoking (more than 10 cigarettes or beedi's/day).

          6. History or presence of asthma, urticaria or other significant allergic reactions.

          7. History or presence of significant gastric and/or duodenal ulceration.

          8. History or presence of significant thyroid disease, adrenal dysfunction, organic
             intracranial lesion such as pituitary tumor.

          9. History or presence of cancer.

         10. Difficulty with donating blood.

         11. Difficulty in swallowing solids like tablets or capsules.

         12. Use of any prescribed or OTC medication during last two weeks prior to dosing in
             period 01.

         13. Major illness during 3 months before screening.

         14. Participation in a drug research study within past 3 months.

         15. Donation of blood in the past 3 months before screening.

         16. Consumption of grapefruit juice, xanthine-containing products, tobacco containing
             products or alcohol for within 48 hours prior to dosing.

         17. Positive screening test for any one or more: HIV, Hepatitis B and Hepatitis C.

         18. History or presence of significant easy bruising or bleeding.

         19. History or presence of significant recent trauma.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr.Gunjan Shah, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Veeda Clinical Research Pvt. Ltd</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Veeda Clinical Research Pvt Ltd</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujrat</state>
        <zip>380 015</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 12, 2014</study_first_submitted>
  <study_first_submitted_qc>November 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2014</study_first_posted>
  <last_update_submitted>November 12, 2014</last_update_submitted>
  <last_update_submitted_qc>November 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Amlodipine, atorvastatin drug combination</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

